Harlan Robins, chief scientific officer of Adaptive Biotechnologies, sold 386,240 shares worth $8.5 million on July 2, 2026, under a pre-scheduled Rule 10b5-1 trading plan established in March. Despite the sale, Robins retained over 1 million shares valued at $21.6 million. The transaction appears to be a diversification move rather than a sign o...

Adaptive Biotechnologies announced plans to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses. William Blair analyst Andrew Brackmann believes the separation could simplify the investment story and create strategic flexibility for the MRD franchise. The Immune Medicine segment is expected to contribute little to valuation...

Adaptive Biotechnologies priced a $300 million offering of 0% convertible senior notes due 2031 (expandable to $345 million with greenshoe option). The company plans to use proceeds to repay its OrbiMed Purchase Agreement, fund capped call transactions at a 100% premium, repurchase $25 million in common stock, and support general corporate purpos...

Adaptive Biotechnologies announced plans to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses to unlock shareholder value. The MRD segment has shown strong growth, increasing revenue from $103 million in 2023 to $212 million in 2025, while the Immune Medicine segment has advanced in drug discovery capabilities. The compan...

U.S. stock futures showed mixed performance on Tuesday following a preliminary U.S.-Iran agreement. The Dow Jones and Nasdaq 100 advanced while the S&P 500 fell slightly. Key movers included SpaceX surging with a market cap nearing $3 trillion, Dave and Buster's dropping 11.44% on weak earnings, Western Digital gaining 4.97% on analyst upgrade, a...